[pubmed] A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk,
Posté : 20 juin 2021 12:00
Urol Oncol. 2021 Jun 16:S1078-1439(21)00220-9. doi: 10.1016/j.urolonc.2021.05.014. Online ahead of print.
ABSTRACT
INTRODUCTION: Advances in neoadjuvant therapy for patients with localized, nonmetastatic, upper tract urothelial carcinoma (UTUC) is needed.
PATIENTS AND METHODS: PURE-02 was a feasibility study enrolling individuals with UTUC, at clinical stage N0M0, with high-risk features according to the modified European Association of Urology definition, based on the presence of either: high-grade disease, multifocality, tumor size ≥2 cm, and/or hydronephrosis. The treatment consisted of 3 courses of 200 mg pembrolizumab, intravenously, every 3 weeks, followed by radical nephroureterectomy (RNU). The endpoints were to assess the safety, pathological responses, and biomarkers.
RESULTS: Ten patients were enrolled between August 2018 and November 2020, 9 (90%) completed the neoadjuvant course. One treatment-related death occurred as a complication of severe myocarditis, myasthenia gravis, hepatitis and myositis. One (14.3%) patient achieved a clinical complete response and refused to undergo RNU. Two (20%) had disease progression and received subsequent chemotherapy, prior to RNU. Overall, 7 patients underwent RNU: one (14.3%) achieved an ypT1N0 response, although this patient was reported to have a cT1 tumor at baseline imaging. The remaining patients were nonresponders. Circulating tumor DNA assay did not identify patients likely to achieve a complete pathologic response.
CONCLUSION: Single-agent neoadjuvant pembrolizumab did not appear to be a promising treatment strategy for patients with biomarker-unselected, high-risk localized UTUC.
PMID:34147313 | DOI:10.1016/j.urolonc.2021.05.014
Source: https://pubmed.ncbi.nlm.nih.gov/3414731 ... 1&v=2.14.4